Home » Stocks » SPPI

Spectrum Pharmaceuticals, Inc. (SPPI)

Stock Price: $3.20 USD -0.09 (-2.59%)
Updated Mar 4, 2021 11:06 AM EST - Market open
Market Cap 498.32M
Revenue (ttm) 109.33M
Net Income (ttm) -160.26M
Shares Out 131.46M
EPS (ttm) -1.37
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 4
Last Price $3.20
Previous Close $3.28
Change ($) -0.09
Change (%) -2.59%
Day's Open 3.30
Day's Range 3.11 - 3.31
Day's Volume 1,004,381
52-Week Range 1.74 - 5.24

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Seeking Alpha - 3 months ago

Spectrum Pharma is down due to two resolvable issues. If the Rolontis PDUFA issue is resolved, the stock may shoot up.

Seeking Alpha - 3 months ago

Spectrum Pharmaceuticals, Inc. (SPPI) CEO Joe Turgeon on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 3 months ago

Spectrum Pharma (SPPI) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the ...

Zacks Investment Research - 5 months ago

Spectrum Pharmaceuticals (SPPI) saw a big move last session, as its shares jumped 7% on the day, amid huge volumes.

Zacks Investment Research - 5 months ago

Investors need to pay close attention to Spectrum (SPPI) stock based on the movements in the options market lately.

Seeking Alpha - 6 months ago

Spectrum Pharmaceuticals, Inc. (SPPI) CEO Joe Turgeon on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 6 months ago

Spectrum Pharma (SPPI) delivered earnings and revenue surprises of 12.12% and -100.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

The Motley Fool - 7 months ago

The company announced the pricing of a public offering of common stock.

24/7 Wall Street - 7 months ago

Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI) announced good news for cancer patients in its midstage trial on Tuesday.

The Motley Fool - 7 months ago

Spectrum scores a key win in the clinic with its experimental lung cancer drug.

The Motley Fool - 7 months ago

These hidden gems have the potential to deliver significant returns to their shareholders over the long run.

Other stocks mentioned: XNCR
Zacks Investment Research - 8 months ago

Spectrum Pharma (SPPI) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

Zacks Investment Research - 8 months ago

Spectrum Pharma (SPPI) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research - 9 months ago

Spectrum Pharma (SPPI) misses bottom-line estimates for the first quarter and records no revenues.

Seeking Alpha - 9 months ago

Spectrum Pharmaceuticals, Inc. (SPPI) CEO Joseph Turgeon on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 11 months ago

Spectrum Pharma (SPPI) reported earnings 30 days ago. What's next for the stock?

The Motley Fool - 1 year ago

Shares jumped even though the company reported disappointing earnings. What can explain the boost?

Zacks Investment Research - 1 year ago

Spectrum Pharma (SPPI) misses bottom-line estimates for the fourth quarter and records no revenues. Shares down.

Seeking Alpha - 1 year ago

Spectrum Pharmaceuticals, Inc.'s (SPPI) CEO Joseph Turgeon on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Progress of its pipeline candidates is likely to have increased Spectrum Pharmaceuticals' (SPPI) operating expenses in the fourth quarter.

Zacks Investment Research - 1 year ago

Spectrum Pharmaceuticals (SPPI) closed the most recent trading day at $3.24, moving -1.52% from the previous trading session.

Seeking Alpha - 1 year ago

Spectrum Pharmaceuticals: Stock Price Drop Vs Disappointing Clinical Data Provides Good Upside

Benzinga - 1 year ago

Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI), which plummeted 60% to $3.50 Thursday in reaction to a negative clinical readout, were rebounding Friday.

Zacks Investment Research - 1 year ago

Spectrum Pharmaceuticals has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

24/7 Wall Street - 1 year ago

Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI) shares were halved on Thursday after the firm provided an update on its midstage cancer study.

Market Watch - 1 year ago

Spectrum Pharmaceuticals Inc. shares fell 17% in premarket trade Thursday after the company said a mid-stage trial of a treatment for non-small cell lung cancer, or NSCLC, missed its main goal.

Zacks Investment Research - 1 year ago

Spectrum Pharma (SPPI) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor in Spectrum Pharmaceuticals.

Zacks Investment Research - 1 year ago

Investors need to pay close attention to Spectrum Pharmaceuticals (SPPI) stock based on the movements in the options market lately.

Seeking Alpha - 1 year ago

Spectrum Pharmaceuticals, Inc. (SPPI) CEO Joseph Turgeon on Q3 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Spectrum Pharma (SPPI) posts a narrower-than-expected loss for the third quarter of 2019.

Zacks Investment Research - 1 year ago

Investors need to pay close attention to Spectrum Pharma (SPPI) stock based on the movements in the options market lately.

Zacks Investment Research - 1 year ago

Spectrum Pharma (SPPI) reported earnings 30 days ago. What's next for the stock?

Seeking Alpha - 1 year ago

Early ORR results in NSCLC with exon 20 mutation for lead candidate poziotinib pushed the stock over $20.00/share in 2018.

Seeking Alpha - 1 year ago

Early ORR results in NSCLC with exon 20 mutation for lead candidate poziotinib pushed the stock over $20.00/share in 2018.

Zacks Investment Research - 1 year ago

Spectrum Pharma (SPPI) beats bottom-line estimates in the second quarter.

Seeking Alpha - 1 year ago

Spectrum Pharmaceuticals, Inc. (SPPI) CEO Joe Turgeon on Q2 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Spectrum Pharma (SPPI) delivered earnings and revenue surprises of 28.13% and -349.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

Spectrum Pharma (SPPI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Benzinga - 1 year ago

The upward trajectory of prescription drug prices in the U.S. has drawn the ire of lawmakers.

Other stocks mentioned: ALXN, NVLN, NVS, ONCE
Seeking Alpha - 1 year ago

In the late 2000s, Spectrum captured the heightened demand of leucovorin shortage with Fusilev. This benefits patients while conferring shareholders one of the most prosperous periods in the c...

Zacks Investment Research - 1 year ago

Spectrum Pharma (SPPI) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research - 1 year ago

Spectrum Pharma (SPPI) misses bottom-line estimates in the first quarter. The company completes sale of its marketed portfolio in March.

Seeking Alpha - 1 year ago

Spectrum Pharmaceuticals' (SPPI) CEO Joe Turgeon on Q1 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Spectrum Pharma (SPPI) reported earnings 30 days ago. What's next for the stock?

Seeking Alpha - 1 year ago

Spectrum Pharmaceuticals had to withdraw its Biologics License Application (BLA) of ROLONTIS after the FDA requested additional information.

Market Watch - 1 year ago

Spectrum Pharmaceuticals Inc. shares slid 7.6% in premarket trade Friday.

About SPPI

Spectrum Pharmaceuticals, a biopharma company, develops and commercializes oncology and hematology drug products. The company is developing ROLONTIS, a novel long-acting granulocyte colony-stimulating for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNá, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of relapsed or refractory non-Hodgkin's lymphoma patients, ... [Read more...]

Industry
Biotechnology
IPO Date
Sep 26, 1996
CEO
Joseph W. Turgeon
Employees
146
Stock Exchange
NASDAQ
Ticker Symbol
SPPI
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for SPPI stock is "Buy." The 12-month stock price forecast is 10.40, which is an increase of 225.51% from the latest price.

Price Target
$10.40
(225.51% upside)
Analyst Consensus: Buy